French imaging software developer Median Technologies has released its 2024 financial results, reporting 10.2% growth during the second half of the year that was driven by acceleration of its iCRO business unit.
The company posted a full-year 2024 revenue of 22.9 million euros ($23.9 million), a 3.3% increase compared with 22.2 million euros ($23.1 million) in 2023. Revenue in the fourth quarter totaled 5.9 million euros ($6.1 million), up 8.3% from 5.4 million euros ($5.6 million) over the same period in 2023.
Median's iCRO business unit provides imaging services to measure drug efficacy in industry-sponsored oncology trials. New iCRO agreements, added footprint in South Korea and Japan, and new master services agreements with global contract research organizations in 2024 drove order backlog growth for 2025, according to CEO and founder Fredrik Brag.
Median expects U.S. Food and Drug Administration 510(k) clearance and marketing authorization, as well as CE marking, for its eyonis Lung Cancer Screening AI-based software as a medical device product in 2025, it said.
